Lv1
36 积分 2022-05-12 加入
Process Development of the Pyrazinecarboxamide Component of Gilteritinib, a FLT3 Inhibitor
8天前
已完结
Targeting Cancer-Associated PCNA with AOH1996 Induces Mitotic Catastrophe and Enhances Cisplatin Therapy in Cervical Cancer
22天前
已完结
Design and Development of DNA Damage Chemical Inducers of Proximity for Targeted Cancer Therapy
3个月前
已完结
Abstract 4580: Novel PCNA inhibitor AOH1996 synergizes with KRAS-targeted therapies in pancreatic ductal adenocarcinoma
4个月前
已完结
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1 resistance mutation in NSCLC: The first-in-human phase 1 trial
4个月前
已关闭
Abstract 5791: Preclinical characterization of NEO-811, a novel molecular glue degrader of ARNT for the treatment of clear cell renal cell carcinoma
4个月前
已关闭
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
4个月前
已完结
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
4个月前
已完结
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
6个月前
已完结
Development of a Cost-Efficient Process Toward a Key Synthetic Intermediate of the EZH2 Inhibitor PF-06821497
11个月前
已完结
皖公网安备34019202002308
